Senescent cell biomarkers

Patent metadata

Field	Value
Publication number	US-12313631-B2
Application number	US-202117517370-A
Country	US
Kind code	B2
Filing date	Nov 2, 2021
Priority date	May 29, 2014
Publication date	May 27, 2025
Grant date	May 27, 2025

Abstract

The invention relates to senescent cell biomarkers and the uses thereof. The invention also extends to methods and kits for detecting senescence, and drug conjugates and pharmaceutical compositions for killing senescent cells.

First claim

The invention claimed is:

1. A method of detecting and killing a senescent cell in a subject, the method comprises measuring the expression of B2MG on the surface of a cell in a sample obtained from the subject, wherein an increased level of expression of B2MG relative to the level of expression detected in a reference sample indicates the presence of a senescent cell in the sample, and administering a cytotoxic agent to the subject in an amount effective to kill the senescent cell.

2. The method of claim 1 , wherein the measuring further comprises measuring the expression of at least two or more senescent cell biomarkers in the sample;
wherein the senescent cell biomarker is selected from DEP-1, NTAL, EBP50, STX4, VAMP3, ARMCX-3, LANCL1, PLD3 and/or VPS26A.

3. The method according to claim 1 , wherein the sample comprises blood, plasma, serum, spinal fluid, urine, sweat, saliva, tears, breast aspirate, prostate fluid, seminal fluid, vaginal fluid, stool, cervical scraping, cytes, amniotic fluid, intraocular fluid, mucous, moisture in breath, animal tissue, cell lysates, tumour tissue, hair, skin, buccal scrapings, nails, bone marrow, cartilage, prions, bone powder, ear wax, or combinations thereof.

4. The method according to claim 1 wherein the subject is an experimental animal or a human.

5. The method according to claim 1 wherein sample is an ex vivo sample or an in vitro sample.

6. The method according to claim 1 , wherein the subject is suffering from cardiovascular disease, cataracts, osteoporosis, type 2 diabetes, hypertension, Alzheimer's disease or dementia.

Assignees

• Univ Leicester

Inventors

• Macip Salvador

Classifications

• G01N2333/918

  Carboxylic ester hydrolases (3.1.1) · CPC title

• G01N2333/705

  Assays involving receptors, cell surface antigens or cell surface determinants · CPC title

• C12Q1/44

  involving esterase · CPC title

• A61K51/02

  characterised by the carrier {, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus} · CPC title

• G01N33/6842

  Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins · CPC title